The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis ...

A new drug to alleviate idiopathic pulmonary fibrosis, a condition where the lungs harden and make breathing difficult, has emerged after 10 years. The U.S. Food and Drug Administration, FDA, recently ...

Ingelheim, GermanyApproval is based on results from Phase III FIBRONEER™-IPF trial, which showed statistically significant improvements in the ...

The investigators hypothesized that AFM might be able to identify unique nanomechanical fingerprints (NMFs) in tissue samples ...

When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF) might be the culprit behind the concerning symptoms. This rare yet devastating lung disease ...

The Program for Pulmonary Fibrosis and Interstitial Lung Disease's mission is to provide state of the art evaluation and treatment for patients with interstitial lung diseases (ILD). The University of ...

VIENNA — Treatment with a novel lysophosphatidic acid receptor 1 (LPA1) antagonist was associated with significant changes in baseline biomarkers of disease in adults with pulmonary fibrosis, based on ...

MILAN ― Numerous unresolved questions surround progressive pulmonary fibrosis (PPF) treatment, according to Elisabeth Bendstrup, MD, PhD, a researcher and clinical professor in the Department of ...

UCSF researchers shed light on how cells under stress can change their identity in harmful ways, contributing to pulmonary ...

Renowned tabla maestro Zakir Hussain passed away at the age of 73 in a hospital in San Francisco, his family announced on Monday. According to their statement, Hussain’s death was caused by ...

Lung cancer remains the leading cause of cancer-related death in the United States. The good news is that early detection ...